No Detail Found!

Comparative Risk of Infections in Rheumatoid Arthritis Patients Treated with Tofacitinib vs. Adalimumab: A Retrospective Study from a Tertiary Center in Saudi Arabia

Author(s)
Basema Mohammad Alshengiti Department of Medicine, King Abdulaziz University Hospital, Jeddah, Saudi Arabia
Yasser Bawazir Department of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
Abstract
Background: Rheumatoid arthritis (RA) is a chronic autoimmune disease that increases patients' vulnerability to both severe and non-severe infections due to immune dysregulation and the use of immunosuppressive therapies. Tofacitinib, a Janus kinase (JAK) inhibitor and adalimumab, an anti-TNF biologic DMARD, are commonly used in RA management but their comparative infection risks remain unclear, especially in local populations. Materials and Methods: A retrospective observational study was conducted at King Abdulaziz University Hospital in Jeddah, Saudi Arabia. Medical records of RA patients treated with either tofacitinib or adalimumab between January 2018 and February 2023 were reviewed. Patient demographics, treatment characteristics and outcomes including infection-related hospital admissions, ER visits and adverse events were analyzed using descriptive and inferential statistics via Jamovi software. Results: A total of 86 RA patients were included (88.4% female; median age 52.5 years). Tofacitinib was prescribed to 54.7% and adalimumab to 45.3% of patients. The two groups were similar in age, sex, BMI and disease duration. Tofacitinib-treated patients had higher rates of seropositivity and were more likely to receive monotherapy, whereas adalimumab-treated patients more frequently received combination therapy with methotrexate. Infection-related hospitalizations (8.5% vs. 10.3%) and major adverse cardiovascular events were comparable between groups. However, ER visits due to pain were significantly more common in the adalimumab group (28.2% vs. 6.4%, p = 0.023), suggesting better symptom control in the tofacitinib group. Conclusion: While infection and cardiovascular event rates did not significantly differ between treatment groups, tofacitinib may provide better pain control, as evidenced by fewer ER visits. Baseline differences such as seropositivity and combination therapy use should be considered in future studies. These findings provide real-world insight into RA treatment safety profiles in a Saudi population.
Publication Details
Page(s) 75-80
Published Journal: Journal of Pioneering Medical Sciences, Volume: 14, Issue: 5, Year: 2025

Request the full text from PASTIC

Keywords
Rheumatoid Arthritis, Saudi Arabia, JAK inhibitors, Adalimumab, Tofacitinib, Infection risk, Biologic therapy
References
Adas .2022 .The infection risks of JAK inhibition. ” Expert Review of Clinical Immunology, 2014323(3) : 253-261.
Szekanecz . .Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician. ” Nature Reviews Rheumatology, 20(2024) : 101-115.
Cohen . .“Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. ” Annals of the Rheumatic Diseases, 76(2017) : 1253-1262.
Van de Putte L.B.A. .2004 .Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. ” Annals of the Rheumatic Diseases, 63(5) : 508-516.
Almoallim ,Hani M.,Laila A.,Alharbi A. .2014 .Rheumatoid arthritis in Saudi Arabia. Saudi Medical Journal, 35(12) : 1442-1454.
Kremer ,Joel M. . .Postapproval comparative safety study of tofacitinib and biological Disease‐Modifying Antirheumatic drugs: 5‐Year results from a United Statesbased rheumatoid arthritis Registry.” ACR Open Rheumatology. , 3(2021) : 232-184.
Choi Se,Rim Se,July Se .2025 .Comparative risk of infections between JAK inhibitors versus TNF inhibitors among patients with rheumatoid arthritis: a cohort study. ” Arthritis Research & Therapy, 25(1) : .
Contreras . .Emergency department utilization by persons with rheumatoid arthritis: a population-based cohort study. Rheumatology International, 44(9) : 1691-1700.
0

Citations

0

Downloads

93

Views